title: Neutralizing activity and antibody reactivity toward immunogenic regions of the human T cell leukemia virus type I surface glycoprotein in sera of infected patients with different clinical states.
abstract: The induction of specific neutralizing antibodies is an important part of vaccine strategy against human T cell leukemia virus type I (HTLV-I). A recently developed reporter gene induction assay was used to detect and quantify neutralizing antibodies in sera of HTLV-I-infected patients with different clinical states: Most sera (73/89) displayed an inhibitory activity. Neutralizing antibodies were more frequently detected in sera of patients with tropical spastic paraparesis/HTLV-associated myelopathy (TSP/HAM) or sicca syndrome (SS) (100%) than in sera of patients with adult T cell leukemia (ATL; 50%) or of asymptomatic carriers (AS; 83%). The mean titers in the different groups were significantly different (ATL < AS < TSP/HAM and SS). The antibody reactivity detected by the reporter gene inhibition assay was significantly related to the recognition of the neutralizable immunodominant domain (aa 175-199) of the surface envelope glycoprotein, indicating the importance of this region for potential vaccines.
authors.affiliation: INSERM, Université de Bordeaux II, France.
authors.forename: T
authors.initials: T
authors.lastname: Astier-Gin
authors.forename: J P
authors.initials: JP
authors.lastname: Portail
authors.forename: D
authors.initials: D
authors.lastname: Londos-Gagliardi
authors.forename: D
authors.initials: D
authors.lastname: Moynet
authors.forename: S
authors.initials: S
authors.lastname: Blanchard
authors.forename: R
authors.initials: R
authors.lastname: Dalibart
authors.forename: J F
authors.initials: JF
authors.lastname: Pouliquen
authors.forename: M C
authors.initials: MC
authors.lastname: Georges-Courbot
authors.forename: C
authors.initials: C
authors.lastname: Hajjar
authors.forename: S
authors.initials: S
authors.lastname: Sainte-Foie
authors.forename: B
authors.initials: B
authors.lastname: Guillemain
mesh_terms: D018604:Epitope Mapping; D015686:Gene Products, env / Q000276:immunology*; D015481:HTLV-I Antibodies / Q000276:immunology*; D015486:HTLV-I Antigens / Q000276:immunology*; D015490:HTLV-I Infections / Q000276:immunology*; D015368:Human T-lymphotropic virus 1 / Q000276:immunology*; D006801:Humans; D015458:Leukemia, T-Cell / Q000276:immunology; D009500:Neutralization Tests; D015493:Paraparesis, Tropical Spastic / Q000276:immunology; D015682:Retroviridae Proteins, Oncogenic / Q000276:immunology*; D012859:Sjogren's Syndrome / Q000276:immunology
chemical_list: D015686:Gene Products, env; D015481:HTLV-I Antibodies; D015486:HTLV-I Antigens; D015682:Retroviridae Proteins, Oncogenic; C055266:gp46 protein, Human T-cell leukemia virus type I